The estimated Net Worth of Timothy M Adams is at least $6.48 Milion dollars as of 29 February 2024. Mr. Adams owns over 15,000 units of Prevail Therapeutics Inc stock worth over $3,834,798 and over the last 17 years he sold PRVL stock worth over $2,381,858. In addition, he makes $261,058 as Independent Director at Prevail Therapeutics Inc.
Timothy has made over 9 trades of the Prevail Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 15,000 units of PRVL stock worth $878,400 on 29 February 2024.
The largest trade he's ever made was selling 15,000 units of Prevail Therapeutics Inc stock on 29 February 2024 worth over $878,400. On average, Timothy trades about 1,747 units every 36 days since 2007. As of 29 February 2024 he still owns at least 170,739 units of Prevail Therapeutics Inc stock.
You can see the complete history of Mr. Adams stock trades at the bottom of the page.
Timothy M. Adams serves as Independent Director of the Company. Mr. Adams currently serves as Chief Financial Officer of BitSight Technologies, Inc., a cyber security ratings company. He previously served as Chief Financial Officer of ObsEva SA from January 2017 to April 2020. From June 2014 to September 2016, Mr. Adams served as the Chief Financial Officer of Demandware, Inc., and prior to that, he served as Senior Vice President and Chief Financial Officer of athenahealth, Inc. from January 2010 to June 2014. Previously, Mr. Adams served as Chief Investment Officer of Constitution Medical Investors, Inc., a private investment firm focused on health-care-sector-related acquisitions and investments, as well as Senior Vice President of Corporate Strategy for Keystone Dental, Inc., a provider of dental health products and solutions. Earlier in his career, Mr. Adams was Chief Financial Officer at a number of other publicly traded companies. Mr. Adams began his career in public accounting at PricewaterhouseCoopers LLP, and is a Certified Public Accountant. Mr. Adams served as a member of the board of directors of ABILITY Network, a private healthcare technology company, from November 2014 to March 2018. Mr. Adams has served as a member of the board of directors of Model N, a public revenue management solutions company, since December 2016. Mr. Adams obtained a B.S. from Murray State University and an M.B.A. from Boston University.
As the Independent Director of Prevail Therapeutics Inc, the total compensation of Timothy Adams at Prevail Therapeutics Inc is $261,058. There are 5 executives at Prevail Therapeutics Inc getting paid more, with Asa Abeliovich having the highest compensation of $2,861,680.
Timothy Adams is 60, he's been the Independent Director of Prevail Therapeutics Inc since 2019. There are 4 older and 7 younger executives at Prevail Therapeutics Inc. The oldest executive at Prevail Therapeutics Inc is Franz Hefti, 72, who is the Chief Development Officer.
Timothy's mailing address filed with the SEC is C/O RAPID7, INC., 120 CAUSEWAY STREET, BOSTON, MA, 02114.
Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over $0 worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth $816,407,705 . The most active insiders traders include Acquisition Corp Eli Lilly ..., Peter A. Thompson a Advisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of $138,767,762. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth $771,407,753.
Prevail Therapeutics Inc executives and other stock owners filed with the SEC include: